ArticleBioinformatics (Oxford, England)2026
ScopeNovo: a de novo peptide sequencing method using spectrum-spectrum similarity to refine the prediction accuracy.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationDe novo peptide sequencing from tandem mass spectra is essential for characterizing unknown proteins, identifying novel post-translational modifications, and analysing samples without reference databases. While recent deep learning models have improved the predicted peptide accuracy, they typically select the predicted peptide sequence based solely on sequence-level decoding scores. Very often, high scores are assigned to peptides without the direct support from the observed mass spectrum.
resultsWe present "ScopeNovo", a de novo peptide sequencing method that improves predicted peptide accuracy by using spectrum-spectrum similarity between the input spectrum and the "representative" spectrum corresponding to the predicted peptide sequence. ScopeNovo generates multiple candidate peptides using an existing peptide de novo sequencing learning model and reranks candidates based on spectrum-spectrum similarity. To test our method, we use π-PrimeNovo as the base learning model. Experimental results on the standard nine-species benchmark datasets V1 and V2 show that ScopeNovo can substantially improve the prediction accuracy. We designed two settings, where Setting 1 is for well-annotated species, and Setting 2 is for species that are not well annotated. For Setting 1, ScopeNovo improves the average peptide accuracies of π-PrimeNovo over the nine species by 6.1% and 4.0% on V1 and V2, respectively. For Setting 2, ScopeNovo can still improve the peptide accuracy of π-PrimeNovo over the nine species by 3.4% and 1.9% on the V1 and V2 benchmark datasets, respectively. Compared to the best-known method, RankNovo, the peptide accuracies over the nine species on V1 and V2 of our method for Setting 1 are 0.711 and 0.737, where the peptide accuracies for RankNovo are 0.687 and 0.682. Even for Setting 2, the peptide accuracies of our method are comparable to those of RankNovo. AVAILABILITY AND IMPLEMENTATION: ScopeNovo is implemented in Python under an MIT license. The source code is freely available at https://github.com/SoSongzhi/ScopeNovo.git. The test data are available at https://doi.org/10.5281/zenodo.23181841.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.